Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 3/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 2/20 | 0.36 |
| ▸ | LITAF | Q99732 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | CTSE | P14091 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18337890 | 1.00 | AADAT (0.37) | AADATUSP30PIK3CATNFLITAF | |
| SCHEMBL18335868 | 0.84 | AADAT (0.38) | AADATUSP30PIK3CATNFLITAF | |
| SCHEMBL18337965 | 0.84 | AADAT (0.38) | AADATUSP30PIK3CATNFLITAF | |
| SCHEMBL18335888 | 0.84 | AADAT (0.38) | AADATUSP30PIK3CATNFLITAF | |
| SCHEMBL18337983 | 0.84 | AADAT (0.39) | AADATCTSDBACE1NR1D1 | |
| SCHEMBL18336217 | 0.82 | RORC (0.42) | AADATPIK3CABACE1 | |
| SCHEMBL18336981 | 0.76 | AADAT (0.46) | AADAT | |
| SCHEMBL18336461 | 0.76 | AADAT (0.43) | AADAT | |
| SCHEMBL18335774 | 0.75 | PDE8B (0.38) | AADAT | |
| SCHEMBL18336491 | 0.75 | AADAT (0.41) | AADATPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3683222-B1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-10-06 | — | — | EP | disclosed |
| EP-3683222-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2020-07-22 | — | — | EP | disclosed |
| US-10065972-B2 | Bicyclic or tricyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-09-04 | — | — | US | disclosed |
| EP-3135674-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20160376289-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
| US-20160376289-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376289-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | CBR3, CBR1, CYCS | AADAT 3986/4885USP30 4198/4885PIK3CA 4530/4885 |
| US-10065972-B2 | Bicyclic or tricyclic heterocyclic compound | CBR3, CBR1, CYCS | AADAT 4071/4885USP30 4176/4885PIK3CA 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.